Reimagining RNA medicine

May 09, 2024

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 09, 2024

Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

May 07, 2024

Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference

May 02, 2024

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024

Apr 30, 2024

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)

Apr 23, 2024

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

Mar 27, 2024

Wave Life Sciences to Present at Upcoming Investor Conferences

Mar 06, 2024

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

Feb 27, 2024

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy